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Abstract
Although NIV is a simple and useful method, considerable variation in its use across countries, regions and hospitals may be 
noted. The patient should be evaluated according to subjective response (respiratory distress, consciousness, problems related 
to mask and airflow), physiological responses (respiration rate, respiratory effort, air leakage) and patient-ventilator compliance 
(gas exchange, pulse oximetry, arterial blood gases). Normalization in respiration rate within 1 or 2 hours after initiation of tre-
atment is one of the most important markers for recovery. The goal is to maintain respiration rate between 20 and 30 breaths/
minute. Reduction in intercostal and supraclavicular retractions, paradoxical respiration and sympathetic activity indicate success 
of treatment. Arterial blood gases are measured within first 2 hours in order to assess pH and CO2; and as needed thereafter. In 
general, NIV is assessed by arterial blood gases, hemodynamic parameters and several laboratory tests. There is limited number 
of studies in NIV. Here, we aimed to assess radiological implications of gas distribution within lung tissue during NIV therapy.
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Introduction
Non-invasive ventilation (NIV) is an esta-
blished method of treatment in type 2 respiratory 
failure. NIV refers to the use of ventilator support 
without an endotracheal or tracheostomy tube. 
Its popularity is increasing in different countries, 
also in Europe. It can be used both in acute and 
chronic respiratory failure, as well as in home-ca-
re end-expiratory intensive care settings. It tends 
to be an alternative to invasive methods due to 
its flexibility and ease of use. 
NIV plays an important role in the treatment 
of acute respiratory failure. It alters the disease 
process in such disorders as an acute exacerbation 
of chronic obstructive pulmonary disease (COPD) 
and shortens the duration of invasive mechanical 
ventilation (IMV), moreover, it decreases the need 
for intubation and invasive ventilation, reducing 
IMV-related complications and risks. NIV is rela-
tively easy to use and well-tolerated by patients. 
It may change the disease process and severity 
when used in an accurate and timely manner. 
NIV can be applied in two different appro-
aches: non-invasive positive pressure ventilation 
(NIPPV) and continuous positive airway pressure 
(CPAP). NIPPV is the combination of inspiratory 
positive airway pressure (IPAP) and positive and 
in-expiratory pressure/expiratory positive airway 
pressure (PEEP/EPAP) provided via a mask. Bi-
phasic positive airway pressure (BiPAP) or non
-invasive pressure-supported ventilation (NIPSV) 
is also used to define NIV. CPAP provides positive 
airway pressure during both inspiration and expi-
ration while BiPAP ensures differential pressure at 
2 levels: IPAP in inspiration and EPAP in expiration. 
Profound understanding of technique and ac-
curate patient selection are essential for success-
ful administration. NIV therapy is assessed within 
first 48 hours (early response) according to objec-
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tive and subjective criteria [1]. Delayed response 
is permanent respiratory acidosis with a clinical 
improvement despite facial mask-delivered NIV 
for 48 hours. Permanent respiratory acidosis is 
≥ 15 mm Hg increase in PaCO2 (when compa-
red to baseline PaCO2) or pH > 7.30 following 
2 hours of NIV. 
Early NIV failure (< 48 hours) after initial 
improvement is assessed according to major and 
minor criteria defined in the literature [2]. Major 
criteria include: respiratory arrest, persistent, 
besides mechanical ventilation respiratory pau-
ses (that is why we avoid spontaneous modes of 
application in ARF) or bradycardia (< 50 bpm), 
hypotension with systolic arterial blood pressure 
< 70 mm Hg and SaO2  < 90% despite FiO2 > 60% 
(refractory hypoxemia). Minor criteria include 
tachypnea with the respiration rate > 35 bre-
aths/min or the increased respiration rate when 
compared to baseline, pH < 7.30 or a decrease in 
pH when compared to baseline, increased ence-
phalopathy score (as rated by Kelly and Matthay 
scale) when compared to previous assessment. 
NIV failure is defined as the presence of one ma-
jor and 2 minor criteria above 24 hours of NIV. 
If no recovery is achieved in the respiration rate, 
encephalopathy score, PaCO2 and pH via facial 
mask-delivered NIV, the patient is repositioned 
to a sitting posture . If minor criteria are present 
despite NIV, endotracheal intubation should be 
considered unless it is contraindicated [3]. 
Although NIV is a simple and useful method, 
considerable variation in its use across countries, 
regions and hospitals may be noted. The patient 
should be evaluated according to subjective 
response (respiratory distress, consciousness, 
problems related to a mask and airflow), physio-
logical responses (respiration rate, respiratory 
effort, air leakage) and patient-ventilator com-
pliance (gas exchange, pulse oximetry, arterial 
blood gases). Normalization in the respiration rate 
within 1 or 2 hours after initiation of treatment is 
one of the most important markers for recovery. 
The goal is to maintain the respiration rate be-
tween 20 and 30 breaths/minute [4]. A reduction 
in intercostal and supraclavicular retractions, 
paradoxical respiration and sympathetic activity 
indicate the success of treatment. Arterial blood 
gases are measured within first 2 hours in order to 
assess pH and CO2; and as needed thereafter [5].
In general, NIV should be assessed by arterial 
blood gases, hemodynamic parameters and seve-
ral laboratory tests. Here, we aimed to assess ra-
diological implications of gas distribution within 
lung tissue during NIV therapy. 
NIV and radiological assessment in chronic 
obstructive pulmonary disease
COPD is a disease that is characterized by 
irreversible airway obstruction usually caused by 
an exposure to inspired toxic particles [6]. The 
disease severity can be classified according to 
pulmonary function test. It may have symptoms 
of the disease and exacerbation risk. Emphyse-
matous changes, lung cancer, remodeling in the 
airway and vasculature, heart failure, cachexia 
and bone demineralization — all of them can be 
seen in COPD [7]. 
Significant reductions in the length of ICU 
and hospital stay, mortality with prevention 
of intubation have been observed by the NIV 
use in acute exacerbations of COPD and hy-
percapneic respiratory failure. During acute 
exacerbations, the respiration rate is increased 
while diaphragm motions are restricted; positive 
end-expiratory pressure is elevated; and ineffec-
tive and insufficient tidal volume is created- all 
which causes hyperinflation by complicating 
sufficient ventilation. NIV therapy relieves 
respiratory muscles effectively, increases tidal 
volume; reduces the respiration rate, decreases 
hypercapnia by improving oxygenation and 
improves shortness of breath by lowering load 
on the diaphragm [8, 9]. 
In studies suggesting that baseline X-ray and 
CT findings can predict a necessity for ventilator 
support in COPD, it was seen that the need for 
NIV was 2.4-fold higher in the presence of mul-
tilobar involvement in X-ray and 47-fold higher 
in the presence of consolidation in CT scan; 
however, further evidence to confirm the useful-
ness of radiological assessment in this terms is 
needed [10–14]. 
Hypercapnia may develop on a  long-term 
basis in patients with severe COPD. To assess 
NIV therapy in such individuals, high-resolution 
CT scans were obtained at baseline and in 1 and 
6-month follow-up. CT scans were processed by 
functional respiratory imaging (FRI) technique. 
This method estimates lobar volumes (ivLobes), 
airway volume (iVaw), airway resistance (iRaw) 
and volume of blood vessels (iVbv). It provides 
information about functional properties of the 
lung such as ventilation-perfusion (VQ), allowing 
us to correlate them with clinical findings [11]. 
NIV therapy during exacerbation of hypercapneic 
COPD results in lower PaCO2 without a need for 
pharmacological therapy, which maintains over 
several months. In addition, exercise tolerance 
is also ameliorated due to improvement in VQ. 
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Decreased hyperinflation is associated with better 
blood gas values. Presumably, the advance in VQ 
results from amelioration of VQ [12]. 
There is an evidence that sonographic as-
sessment of diaphragm thickness may be useful 
to show diaphragm function and its contribu-
tion to respiratory workload. Girou at al. [13] 
reported the measurement of the diaphragm 
thickening fraction ([thickness at inspiration- 
thickness at expiration]/thickness at expiration) 
in this term. 
The Vibration Response Imaging (VRI) is 
a new and non-invasive imaging modality that 
is used to assess initial therapeutic effect of NIV 
in exacerbation of COPD. The VRI objectively 
records lung sounds by computer assistance in 
a 2-dimensional manner [14]. Functional altera-
tions are rapidly visualized in patients receiving 
NIPPV. It is more sensitive than widely used arte-
rial blood gas result such as PaCO2. It is a promi-
sing, novel non-invasive modality to assess initial 
therapeutic effect of NIV and to predict success 
of NIV at early phase [14]. 
Other modalities
The COPD is a heterogeneous systemic con-
dition. Thus, pulmonary functions as rated by 
spirometric measurements alone are inadequate 
to assess and classify disease severity. Today, 
pulmonary imaging methods and quantitative 
imaging techniques can provide temporal fin-
dings about disease in vivo and potentially allow 
monitoring response to treatment. In his textbo-
ok, George R. Washko discussed major imaging 
modalities including computed tomography (CT), 
magnetic resonance imaging (MRI), positron 
emission tomography (PET) and optical coheren-
ce tomography (OCT) [6]. MR imaging can assess 
tissue movements more comprehensively and 
in real time. However, tissue architecture is a li-
miting factor for the use in the lung. To increase 
its appliance, there is a need for an inhaler and 
intravenous contrast materials. Although PET 
scan is used extensively for screening, diagnosis 
and follow-up in malignancy, it may provide new 
perspectives to pathology and pathogenesis of 
disease in pulmonary disorders such as COPD. 
In a study by Vidal Melo et al. [15], it was shown 
that lung perfusion is markedly heterogeneo-
us in mild and moderate COPD. In the study 
by Alford et al. [16], emphysematous changes 
(a regional perfusion defect) are a component of 
parenchymal disease accompanied by vascular 
remodeling. 
Radiological assessment in patients with 
cardiogenic pulmonary edema/congestive heart 
failure undergoing NIV
Respiratory failure resulting from cardioge-
nic pulmonary edema or congestive heart failure 
(CHF) is a condition that can be treated effec-
tively by using non-invasive ventilation (NIV) 
[17–22]. In CHF, pathophysiological changes 
include congestion in pulmonary vascular bed, 
interstitial edema and fluid accumulation in the 
alveoli. This initially causes hypoxemic respira-
tory failure; followed by hypercapneic respiratory 
failure [19, 20]. 
It was seen that there was a significant dif-
ference in the total number of B lines on lung 
ultrasound at mid-axillary line. Transthoracic 
ultrasound was performed to monitor therapeu-
tic effectiveness of CPAP applied in addition to 
standard therapy in patients with decompensated 
heart failure [21]. 
In a  study on assessment of NIV failure 
in neonatal infants by using lung ultrasound, 
Raimondi et al. [22] showed that the presence 
of hyperechogenic, “white lung” appearance is 
associated with NIV failure. 
Pneumonia and NIV
The use of NIV in severe respiratory failure 
due to community-acquired pneumonia is con-
troversial. Risk factors for NIV failure are unclear 
in these patients [23]. There were no significant 
differences at presentation in patients in de novo 
acute respiratory failure group while a reduction 
in the respiration and heart rate one hour after 
initiation of NIV in patients responding to NIV 
therapy was observed. There was a significant 
increase in alveolar-arterial oxygen gradient (A-a-
DO2) even after 24 hours in the group considered 
to be unresponsive to NIV therapy (p ≤ 0.02). 
When the groups were compared, parameters 
predicting NIV failure after one hour included 
elevated heart rate, high A-aDO2 after 24 hours 
and high Opravil score at presentation. However, 
it should be suggested that the success rate was 
higher in the group responsive to NIV therapy. 
Parameters predicting NIV success included less 
involvement in the lung, early NIV reaction and 
persistence of clinical response. 
In a study, Lowrence et al. [9] assessed chan-
ges in respiratory failure due to pulmonary and 
extra-pulmonary causes by using thoracic CT 
scan. Asymmetrical consolidation and ground 
glass appearance are seen in respiratory failure 
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due to pulmonary causes while symmetrical gro-
und glass appearance is observed in respiratory 
failure in extrapulmonary respiratory arrest. In 
both groups, pleural effusions and air bronch-
ogram are diffuse while Kerley B lines and pneu-
matoceles are rare. 
The number of pulmonary lobes involved, 
presence of tachyarrhythmia and degree of hy-
poxemia are major determinants when deciding 
about the NIV therapy in non-ICU settings; in 
addition, increased pCO2, arterial hypotension, 
age and high IPAP values are other indications 
for NIV therapy in non-ICU settings [24]. 
In recent years, electrical impedance tomo-
graphy (EIT) [24, 25] has become the focus of inte-
rest. This is a novel imaging modality used in the 
assessment of distribution of regional pulmonary 
ventilation. A new generation, EIT-based tech-
nique has also been defined to measure regional 
pulmonary perfusion at bedside. Although it is 
a more commonly used method to measure pul-
monary artery pulsatility, it isn’t appropriate for 
pulmonary perfusion measurement. Real-time EIT 
is used to detect, measure and monitor changes 
in pulmonary ventilation and perfusion during 
CO2 insufflation to the pleural cavity. In a study 
on EIT, regional volumes and distribution of re-
gional ventilation were visualized during combi-
ned continuous hyper-gravity and hyper-oxygen 
exposure in a functional manner. Hyper-gravity 
together with thoracic compression due to anti-G 
Trouser inflation lead to decreased regional com-
pression at the xiphoid level; it was also shown 
that these changes are reversible. These findings 
suggest air trapping at posterior region of the 
lung due to closure of the airway during hyper-
gravity. As a result, EIT is an effective method to 
monitor distinct physiological conditions of the 
lungs in a real-time manner [26]. The results of 
the study by Shah et al. [25] revealed that EIT is 
a non-invasive method for monitoring respiratory 
pattern and changes in distribution of ventilation 
in infants with spontaneous respiration. It was 
noted that the differences seen in distribution 
of ventilation in infants were similar to those 
observed in adults. 
The assessment of NIV therapy was perfor-
med by using HRCT in diffuse interstitial lung 
disease. Although the spectrum of diffuse inter-
stitial lung disease is highly heterogeneous, indi-
vidual differences can be seen in response to NIV 
therapy. Treatment success in acute respiratory 
failure may depend on two factors. Firstly, it leads 
to poorer results in usual interstitial pneumonia 
(UIP) when compared to non-specific interstitial 
pneumonia (NSIP) during application of positi-
ve pressure. Secondly, the effectiveness of NIV 
therapy depends on etiology; it provides better 
results in potentially reversible conditions (e.g. 
pneumonia or acute heart failure), whereas poorer 
outcomes are achieved during acute exacerba-
tion in pulmonary fibrosis. It is assessed by the 
following parameters at admission: 1) presence 
of cough and sputum; 2) fever or hypothermia; 
3) abnormal leukocyte count (leukocytosis or leu-
copenia) or elevated C-reactive proteins according 
to local reference limit. NIV can provide complete 
recovery in oxygenation if the underlying cause 
is pneumonia; however, changes are permanent 
when fibrosis is the underlying cause. As a  re-
sult, decision regarding NIV should be based on 
etiology rather than radiological findings in acute 
respiratory failure due to diffuse interstitial lung 
disease [27, 28]. 
In the study by Corral et al. [29], the effect of 
NIV therapy on cardiac dysfunction was assessed 
by echocardiography in patients with obesity 
hypoventilation syndrome (OHS). It was seen 
than mid-term NIV therapy was more effective 
regarding pulmonary hypertension, left ventri-
cular hypertrophy and functional results when 
compared to CPAP and lifestyle changes. 
Although NIV has been increasingly used, 
success isn’t growing consistently. This may be 
caused by the lack of experience and patient- 
-ventilator mismatch; however, the patency of 
the upper respiratory tract also makes signifi-
cant contribution [25]. The patency of the upper 
respiratory tract may be diminished in response 
to positive pressure, resulting in decreased mi-
nute-ventilation. There is a complex interaction 
between genioglossus muscle activity and soft 
tissues. Electromyography can provide informa-
tion regarding movements of the laryngeal musc-
les (genioglossus or cricothyroid muscles) but no 
data can be obtained regarding movements of soft 
tissues. Additional methods are needed to assess 
the patency of the upper respiratory tract. MR 
imaging can provide such information; however, 
it is expensive and cumbersome in patients re-
ceiving NIV. In recent years, it has been suggested 
that sonography can visualize the patency of the 
upper respiratory tract. Endoscopy was used for 
this purpose but the ideal method hasn’t been 
established [29]. 
Conclusion
We hypothesize that in the future, appro-
aches to clinical care and evaluation of NIV the-
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rapy will include some of the above-mentioned 
imaging modalities and standard severity assess-
ment methods of covered diseases. 
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